Caina Technology Co

Caina Technology Co Net Debt / EBITDA

The Net Debt to EBITDA of Caina Technology Co (301122.SZ) as of Oct 28, 2026 is -14.47. In the previous year, Net Debt to EBITDA was -7.69 — a change of 88.15% (lower).

Net Debt / EBITDA

-14.47

YoY

88.15%

Last updated:

Net Debt to EBITDA of Caina Technology Co is 2024 -14.47 . Net Debt to EBITDA of Caina Technology Co was 2023 -7.69 . It decreases by 88.15% lower compared to the previous year.

The Caina Technology Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
3.27 CNY
Jan 1, 2018
3.54 CNY
Jan 1, 2019
1.13 CNY
Jan 1, 2020
-0.64 CNY
Jan 1, 2021
-1.11 CNY
Jan 1, 2022
-6.76 CNY
Jan 1, 2023
-7.69 CNY
Jan 1, 2024
-14.47 CNY
The Caina Technology Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-14.47+88.15%
-7.69+13.84%
-6.76+507.05%
-1.11+73.00%
-0.64-157.01%
1.13-68.08%
3.54+8.06%
3.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Caina Technology Co Stock analysis

What does Caina Technology Co do? Caina Technology Co., Ltd. manufactures medical consumables including puncture needles, syringes, laboratory consumables, and masks. The company's main products are reusable copper base injection needles, aluminum base injection needles, disposable aluminum-plastic inlaid injection needles, safety blood collection needles, sheathed syringes, disposable Sterile syringes, petri dishes, and reagent tubes. Caina Technology exports its products to the United States, the United Kingdom, and the European Union, serving international markets with its medical supplies. The company generates revenue through the sale of its medical consumables to global healthcare providers and distributors. Its product range targets hospitals, clinics, and laboratories requiring reliable medical equipment. Caina Technology's focus on exporting to developed markets ensures steady demand for its high-quality, compliant medical products. Caina Technology's business model relies on manufacturing and exporting medical consumables to international customers. The firm's product portfolio includes specialized items like safety blood collection needles and sterile syringes, which are essential for healthcare facilities. By targeting key regions such as the United States, United Kingdom, and European Union, the company secures consistent sales channels for its medical supplies. Caina Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Caina Technology Co stock

Net Debt to EBITDA of Caina Technology Co is -14.47 in 2024.

Net Debt to EBITDA of Caina Technology Co changed from -7.69 to -14.47, representing a 88.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Caina Technology Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Caina Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Caina Technology Co

All Key Metrics — Caina Technology Co